Galapagos Enters Three-year Collaboration with Roche
News Mar 28, 2006
Galapagos NV has announced that Galapagos' service division, BioFocus, has entered into three-year collaboration with Roche. This agreement builds on the working history between Roche and BioFocus.
Under the terms of the agreement, BioFocus will supply Roche with exclusive chemical compound libraries.
BioFocus will synthesize chemical compound libraries based on Roche's framework structures and provide these collections on an exclusive basis to Roche.
These libraries will be generated using a combination of BioFocus' molecular informatics tools and a wide range of synthetic chemistry capabilities.
BioFocus designs and synthesizes both exclusive as well as non-exclusive (SoftFocus®) chemical compound libraries that can be used in drug discovery programs, including hit finding, lead optimization and patent exemplification.
"We are very pleased with this new agreement to deliver exclusive compound libraries to complement Roche's drug discovery programs," said Onno van de Stolpe, CEO of Galapagos.
"With a strong set of design tools and world-class synthetic chemistry capabilities, BioFocus continues to secure new business by providing high-quality libraries to the pharmaceutical and biotech industries."
Chili Pepper Derived Anti-Obesity Drug Shows Promise in Animal TrialsNews
A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet.READ MORE
Chemical Compound Class Possesses Potential for Treating Zika VirusNews
A new and promising class of chemical compounds has major potential for treating Zika virus and respiratory syncytial virus, or RSV, according to a new study.READ MORE